Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness

IF 12 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Jacc: Cardiooncology Pub Date : 2025-02-01 DOI:10.1016/j.jaccao.2024.11.004

Sara H. Johansen MSc , Torbjørn Wisløff PhD , Elisabeth Edvardsen PhD , Sofie T. Kollerud MSc , Johanne S.S. Jensen MSc , Ginika Agwu BAc , Konstantina Matsoukas MLIS , Jessica M. Scott PhD , Tormod S. Nilsen PhD

{"title":"Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness","authors":"Sara H. Johansen MSc , Torbjørn Wisløff PhD , Elisabeth Edvardsen PhD , Sofie T. Kollerud MSc , Johanne S.S. Jensen MSc , Ginika Agwu BAc , Konstantina Matsoukas MLIS , Jessica M. Scott PhD , Tormod S. Nilsen PhD","doi":"10.1016/j.jaccao.2024.11.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Poor cardiorespiratory fitness (CRF) is associated with a higher symptom burden and an increased prevalence of long-term treatment–related cardiovascular disease risk factors in cancer survivors. However, the magnitude of systemic therapy–related CRF impairment remains unclear.</div></div><div><h3>Objectives</h3><div>The aim of this study was to evaluate the effects of systemic anticancer treatment on CRF and identify physiological determinants underpinning CRF impairment.</div></div><div><h3>Methods</h3><div>A systematic literature search was performed in PubMed, Embase, CINAHL, SPORTDiscus, and the Cochrane Library. The primary endpoint was the change in CRF, measured by peak oxygen consumption (V<span>o</span><sub>2peak</sub>), from before to after systemic treatment. Secondary endpoints included post-treatment differences in V<span>o</span><sub>2peak</sub> between cancer survivors and noncancer control subjects, along with physiological determinants of V<span>o</span><sub>2peak</sub>. Two meta-regressions were conducted to examine the association between CRF and cardiac output and arteriovenous oxygen difference.</div></div><div><h3>Results</h3><div>A total of 44 studies were included, comprising 27 prospective trials (61%; n = 1,234 cancer survivors, median age 52.4 years) and 17 cross-sectional studies (39%; n = 1,372 cancer survivors, median age 54.0 years; n = 1,923 noncancer control subjects, median age 56.0 years). Systemic anticancer treatment was associated with a significant decrease in V<span>o</span><sub>2peak</sub> (weighted mean difference −2.13 mL·kg<sup>−1</sup>·min<sup>−1</sup>; 95% CI: −2.76 to −1.50 mL·kg<sup>−1</sup>·min<sup>−1</sup>). No significant differences were observed between patient subgroups (esophagogastric, breast, and colon or rectal cancers). At a median follow-up of 2 years (range: 6 weeks to 12 years) post-therapy, cancer survivors had a significantly lower V<span>o</span><sub>2peak</sub> (weighted mean difference −6.39 mL·kg<sup>−1</sup>·min<sup>−1</sup>; 95% CI: −7.60 to −5.18 mL·kg<sup>−1</sup>·min<sup>−1</sup>) compared with noncancer control subjects. Reduced arteriovenous oxygen difference was associated with lower V<span>o</span><sub>2peak</sub> (β = 2.55; 95% CI: 2.05-3.06; <em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>Systemic anticancer treatment leads to substantial and sustained impairments in CRF.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 2","pages":"Pages 96-106"},"PeriodicalIF":12.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087324004162","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Poor cardiorespiratory fitness (CRF) is associated with a higher symptom burden and an increased prevalence of long-term treatment–related cardiovascular disease risk factors in cancer survivors. However, the magnitude of systemic therapy–related CRF impairment remains unclear.

Objectives

The aim of this study was to evaluate the effects of systemic anticancer treatment on CRF and identify physiological determinants underpinning CRF impairment.

Methods

A systematic literature search was performed in PubMed, Embase, CINAHL, SPORTDiscus, and the Cochrane Library. The primary endpoint was the change in CRF, measured by peak oxygen consumption (Vo_2peak), from before to after systemic treatment. Secondary endpoints included post-treatment differences in Vo_2peak between cancer survivors and noncancer control subjects, along with physiological determinants of Vo_2peak. Two meta-regressions were conducted to examine the association between CRF and cardiac output and arteriovenous oxygen difference.

Results

A total of 44 studies were included, comprising 27 prospective trials (61%; n = 1,234 cancer survivors, median age 52.4 years) and 17 cross-sectional studies (39%; n = 1,372 cancer survivors, median age 54.0 years; n = 1,923 noncancer control subjects, median age 56.0 years). Systemic anticancer treatment was associated with a significant decrease in Vo_2peak (weighted mean difference −2.13 mL·kg⁻¹·min⁻¹; 95% CI: −2.76 to −1.50 mL·kg⁻¹·min⁻¹). No significant differences were observed between patient subgroups (esophagogastric, breast, and colon or rectal cancers). At a median follow-up of 2 years (range: 6 weeks to 12 years) post-therapy, cancer survivors had a significantly lower Vo_2peak (weighted mean difference −6.39 mL·kg⁻¹·min⁻¹; 95% CI: −7.60 to −5.18 mL·kg⁻¹·min⁻¹) compared with noncancer control subjects. Reduced arteriovenous oxygen difference was associated with lower Vo_2peak (β = 2.55; 95% CI: 2.05-3.06; P < 0.001).

Conclusions

Systemic anticancer treatment leads to substantial and sustained impairments in CRF.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Jacc: Cardiooncology Multiple-

CiteScore

12.50

自引率

6.30%

发文量

106

期刊介绍： JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.